Senvelgo (velagliflozin oral solution) for Cats, 15 mg/ml ^Rx

Cats

• SENVELGO® (velagliflozin oral solution) is the convenient and easy-to-give, once-daily oral solution for diabetes treatment for cats. • Does not require needles for administration; can be given on a small amount of food or directly into the cat’s mouth. • No refrigeration required, before or after opening. • Easy dosing and sustained glycemic control mean less stress for you and your diabetic cat. • Works fast, helping to control your cat’s diabetes in as early as 7 days3,4. • Sign up for autopship and get a 3-month supply delivered to your door*. *Based on cat weight of approximately 5 kg (11 lbs.) References 1. SENVELGO® (velagliflozin oral solution) prescribing information. 2. Data on file at Boehringer Ingelheim. 3. Data on file at Boehringer Ingelheim. 4. SENVELGO® (velagliflozin) Oral Solution [Freedom of Information Summary; NADA 141-568]. St. Joseph, MO: Boehringer Ingelheim Vetmedica, Inc.; 2023.

SENVELGO oral solution is a drug used to lower high blood glucose (sugar) in otherwise healthy cats with diabetes mellitus not previously treated with insulin. SENVELGO oral solution causes glucose to be passed in the urine by preventing the kidneys from reabsorbing glucose back into the bloodstream.cretion.

Boehringer Ingelheim

velagliflozin

15 mg/mL liquid oral solution in a 12 ml bottle or 30 ml bottle.

The most common side effects are diarrhea or loose stool, vomiting, and weight loss. SENVELGO oral solution, like other drugs, may have side effects. Serious side effects have happened with or without warning and sometimes led to death in cats treated with SENVELGO oral solution. Serious side effects may require your cat to be hospitalized and to be given specific treatments, including insulin.

WARNING: DIABETIC KETOACIDOSIS/EUGLYCEMIC DIABETIC KETOACIDOSIS • Cats treated with SENVELGO® (velagliflozin oral solution) may be at an increased risk of diabetic ketoacidosis or euglycemic diabetic ketoacidosis (see Adverse Reactions). As diabetic ketoacidosis and euglycemic diabetic ketoacidosis cats treated with SENVELGO oral solution may result in death, development of these conditions should be treated promptly, including insulin administration and discontinuation of SENVELGO oral solution (see Monitoring). • Due to the risk of developing diabetic ketoacidosis or euglycemic ketoacidosis, do not use SENVELGO oral solution in cats with diabetes mellitus who have previously been treated with insulin, who are receiving insulin, or in cats with insulin-dependent diabetes mellitus (see Contraindications). • SENVELGO oral solution should not be initiated in cats with anorexia, dehydration, or lethargy at the time of diagnosis of diabetes mellitus or without appropriate screening tests (see Animal Safety Warnings). IMPORTANT SAFETY INFORMATION • Keep SENVELGO oral solution in a secure location out of reach of dogs, cats, and other animals to avoid accidental ingestion or overdose. • Cats who are insulin dependent should not be treated with SENVELGO oral solution because it can cause serious, sometimes fatal, side effects. • SENVELGO oral solution, like other drugs, may have side effects. The most common side effects are diarrhea or loose stool, vomiting, and weight loss. Serious side effects have happened with or without warning and sometimes led to death in cats treated with SENVELGO oral solution. • STOP USING SENVELGO ORAL SOLUTION AND CONTACT YOUR VETERINARIAN IMMEDIATELY IF YOU NOTICE ANY OF THE FOLLOWING CHANGES OR SIDE EFFECTS IN YOUR CAT: Less interest in food or not eating, lack of energy or change in normal activity, vomiting or diarrhea, weakness, difficulty walking or standing.

Contact your nearest emergency animal hospital.

SENVELGO® (velagliflozin oral solution) can be stored at or below 77°F (25°C) with excursions permitted up to 104°F (40°C). Once the bottle is opened, use the contents within six months. Keep SENVELGO oral solution in a secure location out of reach of dogs, cats, and other animals to avoid accidental ingestion or overdose.